We have assessed the feasibility of using fixed-limit criteria based on medical relevance and biological variation for evaluating the analytical performance of the prostate-specffic antigen (PSA) test. The estimated within-subject variation of serum PSA is on the order of 10-20% at clinical decision points. The calculated performance goals of 5-10% CV are attainable with current immunoassay technology and agree with precision goals based on clinical experience and the current clinical use of the test. However, new clinicalapplicationsof PSA may require a degree of analytical performance that current methods may not be able to provide. The PSA model demonstrates the need for biologically based fixed-limit criteria for all tumor-marker tests. 
Discussion
Second, when a test like PSA is used in usual clinical practice, it is at significant risk for verification bias or work-up bias, in that not everybody gets the same evaluation. In fact, the rest of the evaluation depends on the test results. That is how usual clinical practice works. When we set up studies to evaluate these sorts of tests, it is important to make sure (to the degree we can) that everybody gets the same evaluation. Again, usual clinical practice would generally limit the number of people who get biopsies-that's one problem with respectto detection of disease.And, some people who have cancer are going to have a benign course, which also may affect detection.
Finally, I want to respond to an earlier statement that sensitivity and specificity are independent of prevalence. I understand entirely that mathematically they should be or perhaps are. Empirically, however, sensitivity and specificity can be shown not be independent of prevalence. The difficulty, I believe, is that there is covariation between comorbidity and prevalence. Groups of people who have a low prevalence of disease have a different disease burden or a mix of diseases than those who are at a higher risk of disease. This can be seen with prostate cancer. Men who are at higher risk of prostate cancer are older; older men tend to have larger prostates (and thus may have false-positive PSAs).
Older men also have lots of other things going wrongmore lung disease, more heart disease, more diabetes, more hypertension.
They have enough trouble trying to do that. In any event, that sort of judgment needs to come from the next level of specialization, the urologist. The potentially benign course of the disease should not impact our detection of the disease. The disease is the second-most common cause of cancer deaths in American men, and its clinical expression is as the most common cancer among American men. This is not to be confused with the prevalence rate of prostate cancer, which is that 1 of every 10 men will have prostate cancer sometime during his lifetime; the statistics about its being the number one cancer and the second cause of cancer death are related to its clinical incidence, not its prevalence rate. That needs to be carefully understood. I wasn't suggesting that we compare the results of the precision studies. But I think that you can use a fixed-limit criteria for your day-to-day quality control, in much the same way you use it to evaluate the
